News

The European Commission has approved expanded use of Novo Nordisk’s Tresiba (insulin degludec) to include children and adolescents with diabetes aged one to 17 years.

The 27th DIA EuroMeeting in Paris, 13-15 April 2015, will be a landmark event. 

GlaxoSmithKline is strengthening its presence in Singapore by establishing a new 15,000-square-metre global headquarters for Asia.

The Health Select Committee has confirmed that its report into health and care spending – originally due this week – will not be published ahead of the general election.

Patients in England and Wales with chronic lymphocytic leukaemia are a step closer to getting access to Roche’s Gazyvaro (obinutuzumab) on the National Health Service, after cost regulators recommended the drug for routine use. 

The first wave of ‘game-changing’ care plans created by frontline healthcare professionals to radically redesign NHS services have been selected for testing and development.

Illumina has signed up another big pharma – this time Merck Serono – to develop a universal, next-generation sequencing-based cancer test ultimately able to select the right personalised cancer drug for each patient.

Consumer-rights law firm Hagens Berman has filed a wrongful death lawsuit against Merck & Co for allegedly failing to warn of dangerous side effects related to its prescription hair loss drug Propecia (finasteride). 

Seventy-nine percent of oncologists taking part in a survey commissioned by Sanofi feel that cuts to England’s Cancer Drugs Fund will compromise their ability to make optimal treatment choices for their patients.

Kythera investors received some good news today after it emerged that US regulatory advisors are backing approval of the firm’s treatment for double chin.

Merck KGaA subsidiary Merck Serono has amended its development and license deal with Opexa Therapeutics for Tcelna, handing over $3 million to further support an ongoing trial with the personalised immunotherapy for multiple sclerosis.

Four NHS Foundation Trusts based in the North of England are to have their books scrutinised by health regulator Monitor after getting into financial difficulties.

NHS England and local councils have announced the first demonstrator sites in the country that will merge health and social care funding for vulnerable individuals and allow them to decide on how it is used.

The Scottish Medicines Consortium has endorsed the use of seven new drugs on the National Health Service, including two biosimilars.

Research funders in the US, Canada and the UK are expanding a global funding initiative to investigate the similarities and differences between different degenerative brain diseases.